GGrantIndex
Sort

51,593 grants matching hepatitis

Gulf Longitudinal Follow-up (GuLF) Study

$1,209,935
Dale P Sandler · National Institute Of Environmental Health Sciences · ZIA · FY2017 · ES

Preclinical Development of a Thermostable Trivalent Filovirus Vaccine

$1,209,712
Axel T Lehrer · University Of Hawaii At Manoa · R01 · FY2019 · AI

Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU)

$1,209,654
Suwat Chariyalertsak · Chiang Mai University · UM1 · FY2016 · AI

Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine

$1,209,546
Andrea L Cox · Johns Hopkins University · U19 · FY2022 · AI

Nuclear receptors: action, functions, and roles in disease

$1,209,453
Anton M Jetten · National Institute Of Environmental Health Sciences · ZIA · FY2012 · ES

Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism

$1,208,754
Steffanie A Strathdee · University Of California, San Diego · R01 · FY2021 · DA

Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care

$1,208,520
Bruce R Schackman · Weill Medical Coll Of Cornell Univ · P30 · FY2015 · DA

Mechanism of oxidative/nitrosative stress and inflammation-induced tissue injury

$1,207,542
Pal Pacher · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2013 · AA

VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT

$1,207,252
Vanderbilt University · U01 · FY2002 · AI

Molecular Biology of Hemorrhagic Shock

$1,207,076
Timothy R Billiar · University Of Pittsburgh At Pittsburgh · P50 · FY2012 · GM

INTERNATIONAL TRAINING GRANT IN EPIDEMIOLOGY RELATED TO

$1,206,496
University Of California Los Angeles · D43 · FY2001 · TW

DEVELOPMENT OF NOVEL THERAPIES FOR NIDDM

$1,206,169
University Of Texas Sw Med Ctr/Dallas · P01 · FY2003 · DK

Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study

$1,206,083
Philip Todd Korthuis · Oregon Health & Science University · UH3 · FY2020 · DA

Macaque and human models for preclinical development of iPSCs

$1,205,414
Cynthia E Dunbar · National Heart, Lung, And Blood Institute · ZIA · FY2014 · HL

Studies of Rare Cancers

$1,205,252
Louise Brinton · Division Of Cancer Epidemiology And Genetics · ZIA · FY2012 · CA

Molecular Subtypes for Targeted Therapies in Alcoholic Hepatitis

$1,205,194
Ramon Bataller · Univ Of North Carolina Chapel Hill · U01 · FY2016 · AA

Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid Receptors

$1,204,486
Kenner Rice · National Institute On Drug Abuse · ZIA · FY2013 · DA

Preclinical Development of a Thermostable Trivalent Filovirus Vaccine

$1,203,584
Axel T Lehrer · University Of Hawaii At Manoa · R01 · FY2020 · AI

Molecular Mechanisms of Pathogenesis of Acute and Chronic Liver Diseases

$1,203,264
Patrizia Farci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI

Addressing alcohol misuse in HIV prevention and care: The Brown University Alcohol Research Center on HIV (ARCH)

$1,203,071
Christopher W. Kahler · Brown University · P01 · FY2022 · AA

DETERMINANTS OF INDIVIDUAL RESPONSIVENESS TO DRUGS

$1,202,331
Vanderbilt University · P01 · FY2004 · GM

Mechanisms of Alcoholic Liver Disease

$1,202,007
Bin Gao · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2010 · AA

Center for CAM Research on Autoimmune and Inflammatory Diseases

$1,201,975
Prakash S. Nagarkatti · University Of South Carolina At Columbia · P01 · FY2007 · AT

Innate immunity and cytokines in liver diseases

$1,201,402
Bin Gao · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2014 · AA

Immunologic Mechanisms of Alcoholic Liver Disease

$1,201,402
Bin Gao · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2014 · AA